Psychedelics Investing Levitee Labs Announces Philip Van Den Berg to Join as Interim CEO and the Board of Directors and Close First Tranche of Private Placement for $1.5 Million
Psychedelics Investing Levitee Labs Signs Retail Distribution Agreement with Body Energy Club for MONKE Nutraceuticals
Psychedelics Investing Levitee Labs Partners with Canntab Therapeutics to Provide Alternatives to Opioids
Psychedelics Investing Levitee Labs Announces Strategic Partnership with LiveRx Research Group to Provide Equitable Access to Hepatitis C Care throughout Alberta, Canada
Psychedelics Investing Stocks2Watch's Virtual Investor Luncheon Agenda Updated for Tuesday November 30
Psychedelics Investing Stocks2Watch to Host Investor Luncheon with Special Guest, Bruce Campbell from StoneCastle Investment Management, Tuesday November 30th
Psychedelics Investing Levitee Labs Signs Letter of Intent to Acquire a Chain of Specialty Addiction Pharmacies Located in British Columbia
Psychedelics Investing Levitee Labs Publishes First Combined Revenue Figures for September 2021 and October 2021
Psychedelics Investing Levitee Labs Signs LOI to Acquire Controlling Interest in a R&D Compounding Pharmacy; Focus to be on Levitee-Branded Products
Psychedelics Investing Levitee Labs Announces Gold Sponsorship of Wonderland Psychedelic Conference in Miami
